Alaunos Therapeutics, Inc
Price
FilingsNewest: 8-K, Material agreementSep 22 →InsidersNo open-market buys or sales.→HoldersBlackRock 0.9%Geode 0.8%Vanguard Fiduciary Trust 0.6%→Financing →
From the filings
Figures
- Revenue
- $3,000last 12 months
- Net income
- −$4.0Mlast 12 months
- Operating cash flow
- −$3.1Mlast 12 months
- Cash and equivalents
- $124,000at the last balance sheet
- Shares outstanding
- 2.5M shareson issue